UltraSPECT Hopes For Sales Boost From Partnership With PharmaLogic

Twitter icon
Facebook icon
LinkedIn icon
e-mail icon
Google icon

UltraSPECT, a Auburndale, Mass., provider of nuclear medicine image reconstruction technology has formed a distribution agreement with PharmaLogic to help get its UltraSPECT's Cardiac and Bone imaging applications for reducing radiopharmaceutical dose and acquisition time into the hands of PharmaLogic’s hospital and imaging center customers.

"Our mission is to help more hospitals and imaging centers to comply with the reduced-dose guidelines recommended by the American Society of Nuclear Cardiology to be effective January 1, 2014. Through our partnership with PharmaLogic, we will be able to supplement our distribution, therefore providing more facilities with the low dose benefit of UltraSPECT's innovative technologies," said Yossi Srour, president and CEO, UltraSPECT in the press release. "We anticipate great demand for the UltraSPECT product line from PharmaLogic customers and look forward to the opportunity to work with other radiopharmaceutical providers in order to help bring UltraSPECT's invaluable products to more healthcare facilities and their patients."